MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'biovail'. Sat, 03 Sep 2011 02:37:54 +0100 http://www.medworm.com/index.php?rid=4893918&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FNdbXFKyzx54%2F Earlier this month, an odd and controversial episode involving a Canadian drugmaker once known as Biovail finally drew to a close. Eugene Melnyk, whose tenure as chairman of Biovail was marked by turmoil and controvery, agreed to sanctions imposed by Canadian securities regulators as a result of misleading disclosures following a 2003 traffic accident involving a shipment of meds. Earlier this year, Biovail, which is now owned by Valeant Pharmaceuticals, agreed to settle a similar lawsuit brought by the US Securities and Exchange Commission, which accused Melnyk and the drugmaker of repeatedly overstating earnings and hiding losses to meet earnings forecasts. And Melnyk agreed to a five-year ban as a director or officer of a public company in the US, and paid $150,000 in fines (back story)... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4893918 Thu, 02 Jun 2011 17:16:19 +0100 4893918 http://www.medworm.com/index.php?rid=4139479&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FtplnNqFKIZU%2F Nearly four years after raising a big stink - and filing a group of $4.6 billion lawsuits - over allegations that research analysts and hedge funds conspired to drive down its stock price, Biovail has finally given up. The white flag was raised, however, only after a recent merger with Valeant Pharmaceuticls that ushered in new management and a new way of viewing a dispute that generated significant publicity and aggravation, but not much else. And so Valeant has agreed to pay $10 million to SAC Capital Advisors to reimburse the hedge fund for the cost of defending two earlier actions filed by Biovail and its shareholders. Both suits against SAC, which is run by billionaire investor Steven Cohen, were dismissed. Moreover, the drugmaker has issued an apology, a rather rare omission, given t... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4139479 Fri, 05 Nov 2010 13:41:00 +0100 4139479 http://www.medworm.com/index.php?rid=4139481&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FYx4Lr3S96k8%2F Good morning, everyone. And we are happy to say that the time has come to daydream - just a wee bit - about the weekend. With any luck, we hope to catch up on some reading, perhaps see a movie and frolic with the short people. Never mind the leaves piling up. What about you? A drive in the country? Dinner with someone special? Whatever you do, have a good time. Meanwhile, here are some tidbits. See you soon… FDA Approves Lilly’s Cymbalta For Chronic Musculoskeletal Pain (Reuters) Roche Melanoma Drugs Shows Promise In Study (Reuters) Canada’s Share Of Health Spending To Drop (PharmaTimes) Acceleron Cuts 40 Percent Of Its Workforce (Boston Globe) Teva Backs 2015 Goals (The Wall Street Journal) Zydus Claims Injunction Against Generic Strattera Doesn’t Apply (Law.com) G... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4139481 Fri, 05 Nov 2010 12:06:46 +0100 4139481 http://www.medworm.com/index.php?rid=3965703&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FDWqutsIp8sY%2F Following through on plans announced earlier this year, Lonza is eliminating 106 jobs from its plant in Conshohocken, Pennsylvania, which makes various pharmaceutical ingredients. The Swiss company, which recently signed supply deals with GlaxoSmithKline and Human Genome Sciences (see here and here), confirmed the planned job losses in a filing with the Pennsylvania Department of Labor. At the time the closure was first announced in January, Lonza also signaled plans to shutter two other plants - one in Shawinigan, Canada, and another in Workingham, UK - and eliminate a total of 175 jobs. A report at the time indicated that about 140 people work at the Conshohocken facility, although the status of those jobs is not clear. Lonza employs about 8,500 people worldwide. This is only the latest ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3965703 Mon, 13 Sep 2010 12:04:56 +0100 3965703 http://www.medworm.com/index.php?rid=3946684&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FEqxTh8_CSgg%2F Just one month after agreeing to buy Penwest Pharmaceuticals for $144 million, Endo Pharmaceuticals is in the process of laying off sales managers and sales reps, according to sources. The exact number of jobs to be eliminated is unclear at the moment, but we are told Endo is engaging InVentiv, a contract sales organization, to provide replacements and lower expenses. We await a reply from Endo. This is not the only dismal jobs news in the pharmaceutical industry this week. As noted earlier, the recently announced $3.2 billion merger between Biovail and Valeant Pharmaceuticals will cause about 25 percent of the combined, 4,000-person workforce to be shown the door, according to this email sent by ceo Mike Pearson to employees yesterday. And Scrip News reported today that Shionogi is cuttin... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3946684 Wed, 08 Sep 2010 18:43:07 +0100 3946684 http://www.medworm.com/index.php?rid=3845286&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FPw1WMPduq3k%2F Hello, everyone, and welcome to another working week - unless you happen to be on vacation. For those of us who remain very much grounded in the routine, however, today ushers in yet another series of meetings and deadlines. So please join us for the mandatory cup of stimulation as we scan the news of the world. We hope your weekend was refreshing and today is a good one. Stay in touch… Avastin Gives Best Lung Cancer Survival Rate: Study (Reuters) FDA Cites Dendreon For Misleading Provenge Material (Dow Jones) Gastroenterologists Prescribing Humira Off Label For Ulcerative Colitis (PharmaTimes) India’s Lambda Buys Biovail’s CRO (Outsourcing Pharma) SSRIs Are Not Effective For Autism: Study (PharmaTimes) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3845286 Mon, 09 Aug 2010 11:43:19 +0100 3845286 http://www.medworm.com/index.php?rid=2800320&cid=t_120040_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2009%2F09%2Fbiovail-settles-and-judge-explains-why.html Last year, we posted about the guilty plea by the US arm of the Canadian firm Biovail to charges that it paid physicians kickbacks to prescribe a long-acting version of the drug diltiazam. This week, the plea was formalized, per Reuters,A U.S. unit of Canadian drugmaker Biovail Corp (BVF.TO) has pleaded guilty to conspiracy and kickback charges, ending a case over its Cardizem hypertension drug, the U.S. Justice Department said on Monday.Prosecutors said Biovail has been sentenced to pay $22.2 million in fines, formalizing an agreement reached last year. It also agreed to pay $2.4 million to settle civil claims. Both involved charges it improperly paid doctors and other prescribers up to $1,000 to recommend Cardizem.When we originally posted about this case, we focused on the unprofessiona... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=2800320 Tue, 15 Sep 2009 20:44:00 +0100 2800320 http://www.medworm.com/index.php?rid=1945452&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F445486132%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? Amarin named Lars Ekman to its board; Critical Outcome Technologies named Michael Cloutier as ceo; Becton Dickinson hired David Elkins as cfo; Becton Dickinson promoted Vincent Forlenza to president; Biovail hired H. Christian Fibiger as senior vp and chief scientific officer; Tracon Pharmaceuticals appointed Bryan Leigh as chief medical officer; Novexel tapped Ken Coleman ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1945452 Fri, 07 Nov 2008 12:30:10 +0100 1945452 http://www.medworm.com/index.php?rid=1945453&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F445430140%2F Yes, the end of the week is fast approaching. What will you do be doing after putting aside work? Raking leaves? Puttering around the house? Escaping to the movies? Whatever your fancy, we hope you have a nice time. Meanwhile, here are a few items to help you along. By the way, we will be leaving early today for an excursion with one of the short people, but will be back to keep tabs on the American Heart Association meeting… Novo Nordisk To Build Diabetes Plant In China (The Financial Times) Biovail Is Searching For Acquisitions (The Globe and Mail) India Plans Testing Zones At Airports (inPharmaTechnologist) Charles River Labs Hurt By Credit Crisis (CNBC.com) Daiichi Completes Purchase Of Ranbaxy Labs (Reuters) Glaxo Sued Over Paxil And Birth Defects (The Brampton Guardian) (Sourc... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1945453 Fri, 07 Nov 2008 12:29:59 +0100 1945453 http://www.medworm.com/index.php?rid=1742941&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F378000142%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? Barton Cobert MD is now doing drug safety consulting at BLCMD Associates; Oxford BioMedica ceo Mike McDonald has left; Biovail hired Neil Sussman as vp, neurologic and psychiatric development; Biovail hired Peggy Mulligan as chief financial officer; Sepracor hired Richard Ranieri as executive vp, human resources; Sepracor hired Julio Casoy as senior vp, medical affairs; Som... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1742941 Fri, 29 Aug 2008 11:28:32 +0100 1742941 http://www.medworm.com/index.php?rid=1660993&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F348493502%2F After winning a court ruling just last week, Eugene is now backing off on his vow to oust the Canadian drugmaker’s board and elect his own team at a rescheduled Biovail shareholder meeting next month, Reuters reports. Instead, Melnyk, who is Biovail’s biggest shareholder, now plans to develop his own private drugmaker, which he will call Trimel Biopharma. The moves come just days after an Ontario judge ruled that a vote on electing the Biovail board at the June 25 shareholder meeting was taken improperly, and he ordered Biovail to reconvene its annual shareholders meeting. In trying to reassert control over Biovail at the June meeting, Melnyk proposed a new emphasis on Biovail’s pipeline, including a return to making generics and acquiring more products and technologies.... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1660993 Mon, 28 Jul 2008 15:33:30 +0100 1660993 http://www.medworm.com/index.php?rid=1649304&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F343939817%2F When we talk about shrinkage, we usually toss out the number of jobs being cut. But another way to look at consolidation is to track all the plants closing. Since January 2007, a total of 77 industry sites employing more than 14,000 people were either closed or have been put on notice, according to Industrial Info Resources, a research firm. Among the 26 that are still scheduled to be shuttered is an AstraZeneca facility in Ontario; a pair of Biovail plants in Puerto Rico; a Bristol-Myers Squibb facility in Puerto Rico, and a Barr Pharmaceuticals plant in New Jersey. “Some of the plants targeted for closure will undoubtedly be reopened by others. With companies eager to shed the buildings, and often the equipment inside, some good deals come on the market…Others, like Pfizer i... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1649304 Wed, 23 Jul 2008 21:42:44 +0100 1649304 http://www.medworm.com/index.php?rid=1631581&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F337214247%2F Eugene Melnyk shoots and scores. The former Biovail ceo and founder, who owns The Ottawa Senators hockey team, was handed a victory today by a Canadian court, which ordered a new vote by Biovail shareholders, Reuters reports. The ruling came after Melnyk challenged procedures at the June 25 Biovail shareholders meeting at which he lost a proxy fight to displace the drugmaker’s board. Melnyk subsequently argued in court that the meeting proceeded without a quorum. Melnyk had withdrawn his dissident slate of directors before the vote, leaving the meeting with less than half of the company’s stock represented. The Biovail board then hastily amended the bylaws to allow the vote to proceed with only 25 percent of the shares represented. (Back story). A new meeting was ordered to be... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1631581 Wed, 16 Jul 2008 16:30:16 +0100 1631581 http://www.medworm.com/index.php?rid=1500288&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F306044771%2F The proxy battle between Biovail founder Eugene Melnyk and the drugmaker’s current management is getting a wee bit personal. Earlier this week, Melnyk, who recently resigned from the board and is now promoting his own slate of directors, charged that Biovail has a ‘dysfunctional board.’ Now, Biovail ceo Bill Wells is taking slap shots at Melnyk, who owns the Ottawa Senators, by the way. In a letter to shareholders, Wells writes that what Melnyk’s calls ‘the golden years’ are actually the ‘lost years,’ from 2001 to 2007, when he was ceo or chairman. And that most of his proposed directors are not independent because they have or did have business relationships with him. “What this is all about is Eugene Melnyk trying to take control of t... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1500288 Fri, 06 Jun 2008 11:42:33 +0100 1500288 http://www.medworm.com/index.php?rid=1458473&cid=t_120040_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2008%2F05%2Fbiovail-pleads-guilty.html As reported by by Fortune (via CNNMoney.com):The big Canadian drug company [Biovail Pharmaceuticals] agreed Friday to plead guilty to U.S. kickback and conspiracy charges. The decision, which closes out a federal investigation of the company's unusual actions in support of a 2003 drug launch, means Biovail (BVF) and a New Jersey-based subsidiary will pay a $24.6 million fine to avoid a court case that could have cost them future business with federal agencies.The marketing program in question - Proving Cardizem LA through Clinical Experience, or PLACE - aimed to build physician awareness of Biovail's 2003 launch of a crucial product, the long-acting formulation of heart drug Cardizem. Skeptical hedge funds and research outfits charged that by paying doctors up to $1,000 for prescribing the... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=1458473 Tue, 20 May 2008 20:48:00 +0100 1458473 http://www.medworm.com/index.php?rid=1454364&cid=t_120040_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F05%2Fbiovail-case-of-hubris.html Biovail's plea bargain doesn't just close an ugly chapter in the Toronto-based company's history. It also pulls the rug out from under a multiyear quest by the company's former management, led by onetime CEO Eugene Melnyk, to blame an alleged conspiracy of hedge funds and research analysts for Biovail's financial and legal woes.Roddy Boyd in FORTUNE has more. (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1454364 Tue, 20 May 2008 11:31:00 +0100 1454364 http://www.medworm.com/index.php?rid=1449571&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F291899211%2F The drugmaker was accused of paying docs as much as $1,000 and their office managers $150 each to get patients to use its Cardizem heart drug as part of a study that was to have been published. To extricate itself, Biovail agreed to pay $24.6 million to settle a Justice Department investigation into the 2003 launch of a long-actng version. “This is an important and positive result for Biovail and its shareholders,” ceo Bill Wells says in a statement, “as the agreement eliminates the significant exposure to the corporation related to this matter and should immediately reduce our ongoing legal expenses.” But the aggravation hasn’t ended entirely. The Securities and Exchange Commission two months ago charged the Canadian drugmaker and several former and current senior execs ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1449571 Sat, 17 May 2008 03:59:16 +0100 1449571 http://www.medworm.com/index.php?rid=1399365&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F277571033%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs being announced each month. Despite downsizing, there is movement. Here are some of the latest changes. Recognize anyone? Gilead Sciences hired Robin Washington as senior vp and cfo; Biovail named Bill Wells, a board member, as ceo; Biovail named interim ceo Doug Squires as chairman; Cell Therapeutics hired Craig Philips as its new president; BioReliance appointed John Kolman and sr director R&D; Metabasis Therapeutics added Elizabeth Stoner to its board; Aeterna Ze... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1399365 Fri, 25 Apr 2008 11:36:47 +0100 1399365 http://www.medworm.com/index.php?rid=1391302&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F275343419%2F Bill Wells, the drugmaker’s new ceo, may excel at cutting costs, but it remains to be seen whether he can boost sales and a flagging stock price. “I think he’ll strip the company down to its bare bones and act very much like a private-equity firm,” David Lickrish, an analyst at Broadpoint Capital, tells The National Post. “But that doesn’t address the broader issue of developing Biovail’s drug pipeline.” Canada’s biggest publicly traded drugmaker yesterday named Wells, the cfo of the Loblaw supermarket chain, to next month replace Doug Squires, who will become chairman. Wells has been a Biovail director since 2005, but spent most of his career in the food industry, including being “actively involved” in the reorganization of... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1391302 Tue, 22 Apr 2008 11:39:23 +0100 1391302 http://www.medworm.com/index.php?rid=1361150&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F267133866%2F The string of issues facing this pill - brand-name and generic - is enough to leave you, well, depressed. For instance, the FDA continues to investigate a generic version of the antidepressant that is marketed by Teva Pharmaceuticals, due to adverse events reported to the agency. Now, some of the 300 milligram brand-name Wellbutrin XL, which is made by Biovail and sold in the US by Glaxo, has been recalled because foreign materials were embedded within the tablets, according to the FDA. Meanwhile, Anchen Pharmaceuticals, which sells a 300 milligram generic Wellbutrin, may have succeeded in getting its pill to market by poaching key employees from an unnamed rival, according to a lawsuit filed in a California state court by a former Anchen employee. An example cited was David Balucci, who w... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1361150 Wed, 09 Apr 2008 17:01:58 +0100 1361150 http://www.medworm.com/index.php?rid=1323238&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F257110046%2F In a complaint filed today, the Securities and Exchange Commission accuses the Canadian drugmaker and several former and current senior execs with engaging in fraudulent accounting schemes and making misstatements to analysts and investors. The execs facing charges are former chairman and ceo Eugene Melnyk; former cfo Brian Crombie; the current controller, John Miszuk; and current cfo Ken Howling. Biovail settled the charges and will pay a $10 million penalty. The SEC complaint alleges that “present and former senior Biovail executives, obsessed with meeting quarterly and annual earnings guidance, repeatedly overstated earnings and hid losses in order to deceive investors and create the appearance of achieving earnings goals. When it ultimately became impossible to continue concealin... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1323238 Mon, 24 Mar 2008 16:13:41 +0100 1323238 http://www.medworm.com/index.php?rid=1300625&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F250853752%2F Eugene Melnyk, who owns The Ottawa Senators hockey team, wants to ice the board and replace it with his own nominees at the drugmaker’s upcoming annual meeting, according to The Canadian Press. The maneuvering comes after Biovail reported a fourth-quarter loss and announced a strategic review of its business. The loss was attributable, in part, to hefty charges due to competition from generics, particularly its version of Wellbutrin XL, and litigation charges. “Beyond 2008, in the next two, three, four years, (we) see incredible growth,” Doug Squires, Biovail’s ceo, tells Reuters. “We’re approaching the point where the old Biovail is turning into the new Biovail.” But Melnyk, who owns nearly 11.7 per cent of the stock and is considering a plan to... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1300625 Thu, 13 Mar 2008 16:36:41 +0100 1300625 http://www.medworm.com/index.php?rid=1194998&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F227370298%2F The Canadian drugmaker says the US Attorney in Boston is investigating activities surrounding its 2003 launch of the blood pressure med, and both civil and criminal charges may result. At issue is a program called PLACE - Proving LA through Clinical Experience - that the drugmaker used to encourage docs to prescribe the pill. (LA refers to longer acting). As the WSJ Health Blog reminds us, Biovail was happily payed docs up to $1,000 and gave office managers as much as $150 to persuade them to participate, a Biovail spokesman at the time explained that the program was supposed “generate physician survey data” that would be published. Nothing like money well spent. “Biovail has cooperated fully with the investigation, and will continue to cooperate,” Biovail says in a sta... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1194998 Fri, 01 Feb 2008 17:59:05 +0100 1194998 http://www.medworm.com/index.php?rid=1068802&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F194928633%2F Those cold winds are finally starting to dissipate, but now the flurries have emerged. This can only mean one thing - time for a cup of something hot and a chance to catch up on the items that came in with the breeze. Here they are…. Merck Forecasts Higher Profits In 2008 (Bloomberg News) King Pharma Loses Rehearing Bid On Altace Patent (HealthLaw360) Biovail And Watson Reach Deal On Cardizem (Yahoo/Reuters) Eisai Buys Rights To BioArctic’s Alzheimer’s Antibody (Bloomberg News) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1068802 Tue, 04 Dec 2007 12:40:13 +0100 1068802 http://www.medworm.com/index.php?rid=1040247&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F187797000%2F Why not? A holiday in the US may be nearing, but the work is piling up. What better way to recharge than to grab a cup of something hot and stare into your screen at the latest developments? And here they are… Biovail Gets Disappointing News From FDA; Stock Falls (Yahoo/AP) Ranbaxy Looks To Split R&D Unit, Buy A CRO (Economic Times) FDA OKs New Indication For Bristol’s Abilify (Yahoo/Reuters) Aegerion Pharma Refiles For IPO (Yahoo/AP) Barr Challenges Patents On ADHD Drugs (Yahoo/Reuters) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1040247 Tue, 20 Nov 2007 16:55:58 +0100 1040247 http://www.medworm.com/index.php?rid=1015062&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F181832026%2F Apologies for the interruption. We are now on a train that is hurtling toward Manhattan, where we will tape an interview with a Web TV site about the pharma biz and blogging and who knows what else. These periodic opportunities offer a welcome respite, but still, we continue to troll for interesting tidbits. We have, in fact, been busy working on a few for your enjoyment in coming days. Meanwhile, we hope these will satisfy…. King Pharma Stock Jumps On Earnings Report (MarketWatch) Biovail Posts A Profit But Revenue Slides (Yahoo/Reuters) Barr Labs Disappoints With Earnings And Outlook (Yahoo/AP) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1015062 Thu, 08 Nov 2007 21:03:36 +0100 1015062 http://www.medworm.com/index.php?rid=979399&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F175048958%2F Why? The issue appears to be generic equivalency. Some people reported having headaches, anxiety and other ailments. And the agency is also reviewing the scientific formulation of the drug, called Budeprion XL, after a consumer-product testing group published results that showed key differences from the original drug, according to the Associated Press. The tests, conducted by ConsumerLab.com, came after Budeprion XL users earlier this year began complaining that the drug caused severe headaches, digestive problems, anxiety, tremors, and insomnia. Another Web site, peoplespharmacy.com, reported that more than 250 people had complained about the drug. Budeprion XL is made by Impax Laboratories and sold by Teva Pharmaceutical. Impax declined to comment and Teva representatives did not immedia... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=979399 Fri, 26 Oct 2007 01:00:05 +0100 979399 http://www.medworm.com/index.php?rid=856913&cid=t_120040_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F154547931%2F Who’s a hockey puck? The Canadian drugmaker, which is suing 22 research analysts and hedge funds for allegedly conspiring to drive down its stock price, has agreed to drop its claim again Dave Maris (that’s him to the left) and his employer, Banc of America Securities, The New York Post reports. What’s more, Biovail also agreed to pay the firm $2 million in legal fees, according to a person familiar with the proceedings. The lawsuit alleged that Maris intentionally published misleading research on Biovail so that a hedge fund client, a unit of SAC Capital Advisors, could profit from a decline in its stock price. Though Biovail’s former chairman, Eugene Melnyk, was supposedly confident about his case against Maris, the paper writes that Biovail’s evidence wasn... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=856913 Mon, 10 Sep 2007 11:23:30 +0100 856913 http://www.medworm.com/index.php?rid=624608&cid=t_120040_150_f&fid=35603&url=http%3A%2F%2Fdrugreptoys.blogspot.com%2F2006%2F10%2Fcardizem-calipers.html EKG calipers are wonderful things. They are a badge of sorts, declaring in an instant that "I am an internist." These are quite serviceable. (Source: Drug Rep Toys) Drug Rep Toys blogs http://www.medworm.com/rss/comments.php?id=624608 Fri, 27 Oct 2006 07:09:00 +0100 624608